Cadrenal Therapeutics, Inc. , a biopharmaceutical company developing novel therapeutics for patients with cardiovascular disease, today announced new findings from third-party research on the economic ...

With the factor XI inhibitor, clinicians may have more flexibility when managing anticoagulation in this common scenario.

Based on these numbers, the researchers estimated that 5-year cumulative risks of recurrent events were 17.4% for ischemic ...

Community cardiology specialist Dr Peter Savill discusses five key challenges for GPs in the management of atrial ...

There is an apparent underuse of warfarin in elderly patients with AF, as there is inconsistency in opinion among clinicians about who should receive anticoagulation. The risks of warfarin are ...

I've been diagnosed with atrial fibrillation. I've read that it puts me at greater risk of stroke. Can you tell me more about ...

As we observed World Heart Rhythm Week (June 2–8, 2025), the theme “One Heart, Many Rhythms” underscored the importance of ...

– For people who have heart failure with a normal heart rhythm, there seems to be little to no advantage of warfarin (an anticoagulant: a medicine which prevents blood clotting by blocking proteins) ...

Atrial fibrillation (AF) is the most common cardiac arrhythmia, and its incidence increases with age. Current data suggest that anticoagulation with warfarin or dabigatran is far superior to ...

Loss of lifetime improved for patients with complications including stroke, HF and heart attack after a new atrial ...

Patients with AF and ACHD that receive NOAC, compared with VKA, for stroke prevention have lower risk of all-cause mortality.

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...